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BACKGROUND: CYP2C8/9 polymorphisms may influence breast cancer-free survival after diagnosis due to their role in the metabolism
of tamoxifen, paclitaxel, and other chemotherapy. cytochrome P450 (CYP)2C8/9 metabolise arachidonic acid to epoxyeicosatrienoic
acids, which enhance migration and invasion in vitro and promote angiogenesis in vivo. We aimed to investigate the frequency of
CYP2C8/9 polymorphisms in relation to breast tumour characteristics and disease-free survival.
METHODS: A prospective series of 652 breast cancer patients from southern Sweden was genotyped for CYP2C8*3, CYP2C8*4,
CYP2C9*2, and CYP2C9*3. Blood samples and questionnaires were obtained pre- and postoperatively. Clinical information and
tumour characteristics were obtained from patients’ charts and pathology reports.
RESULTS: Frequencies of CYP2C8/9 polymorphisms were similar to healthy European populations. Significantly less node involvement
(P¼0.002) and fewer PRþ tumours (P¼0.012) were associated with CYP2C8*4. Median follow-up was 25 months and 52 breast
cancer-related events were reported. In a multivariate model, CYP2C8/9*3/*1*/*2/*1 was the only factor associated with increased
risk for early events in 297 tamoxifen-treated, ER-positive patients, adjusted HR 2.54 (95%CI 1.11–5.79). The effect appeared to be
driven by CYP2C8*3, adjusted HR 8.56 (95%CI 1.53–51.1).
CONCLUSION: Polymorphic variants of CYP2C8/9 may influence breast tumour characteristics and disease-free survival in tamoxifen-
treated patients.
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In Sweden, approximately 7000 women are diagnosed with breast
cancer annually and 1500 die of their disease. Up to 25% of breast
cancer patients considered to be at low risk for recurrence, that is,
stage-I or II without lymph node involvement, recur within 5 years
(Malmstro ¨m et al, 2001, 2003). Approximately 15% of all breast
cancer patients in Sweden die from their disease within 5 years and
30% die within 10 years of diagnosis. Adjuvant therapies such as
radiation, tamoxifen, aromatase inhibitors (AIs), and chemo-
therapy improve the prognosis, but also confer a risk of adverse
side effects (Early breast cancer trialists’ collaborative group, 2005;
Forbes et al, 2008). Moreover, many patients receive adjuvant
therapy without any impact on survival, as most are already cured
by surgery alone or the adjuvant therapy chosen does not work as
intended. Markers, which would help to better tailor adjuvant
therapy to each patient, are urgently needed.
Several genetic polymorphisms in genes such as cytochrome-
P450 (CYP)2C8 and CYP2C9, may influence survival after cancer
diagnosis due to their role in the metabolism of various breast
cancer drugs, including tamoxifen and chemotherapy (Jin et al,
2005). CYP2C8 and CYP2C9 are polymorphic enzymes. CYP2C8*3
and CYP2C9*2 are the major variant alleles in Caucasian
populations (Yasar et al, 2002). Approximately 96% of subjects
with the CYP2C8*3 allele also carried a CYP2C9*2 and 85% of
subjects who had the CYP2C9*2 variant also carried a CYP2C8*3.
CYP2C8*3 is defective in the metabolism of two important CYP2C8
substrates: the anticancer drug paclitaxel (Bahadur et al, 2002) and
the physiologically important compound arachidonic acid (AA)
(Dai et al, 2001). In addition, variants CYP2C8*4 and CYP2C9*2
and CYP2C9*3 also have a lower metabolic activity than the wild-
type variants (Bahadur et al, 2002; Griskevicius et al, 2003; King
et al, 2004; Sandberg et al, 2004).
Arachidonic acid is metabolised via three major pathways: the
cyclooxygenase pathway, which produces prostaglandins; the
lipoxygenase pathway, and finally the CYP epoxygenase pathway
(Belton and Fitzgerald, 2003).
CYP2C8 and 2C9 are CYP epoxygenases, which metabolise AA
to epoxyeicosatrienoic acids (EETs) (Zeldin et al, 1995; Michaelis
et al, 2005), with the most abundant product being 14,15-EET,
which promotes angiogenesis in vivo (Medhora et al, 2003).
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angiogenesis via activation of the epidermal growth factor receptor
(EGFR) (Michaelis et al, 2003). Jiang et al (2007) showed that CYP
epoxygenase overexpression enhanced tumour metastasis of
MDA-MB-231 human breast carcinoma cells to the lungs of
athymic BALB/C mice. Moreover, CYP epoxygenase overexpres-
sion or EET treatment markedly enhanced the migration, invasion,
and prometastatic gene expression profiles in a variety of cancer
cell lines in vitro (Jiang et al, 2007). Functional polymorphisms of
CYP2C8 and CYP2C9 may thus be of importance for breast cancer
risk, tumour characteristics, and treatment response.
Our study has four interrelated aims: first, to investigate the
frequency of the polymorphic variants CYP2C8*3, CYP2C8*4,
CYP2C9*2, and CYP2C9*3 in a series of breast cancer patients;
second, to construct CYP2C8/9 haplotypes; third to determine
whether these genetic variants were associated with breast cancer
characteristics of prognostic importance; and fourth, to investigate
whether any of these genetic variants were associated with early
breast cancer-related events.
MATERIALS AND METHODS
Women assessed preoperatively at the Lund University Hospital and
the Helsingborg Hospital, Sweden, for a first breast cancer were
invited to take part in an ongoing study regarding genetic and non-
genetic factors that could be associated with breast cancer prognosis
and treatment response. Patients were included between October
2002 and October 2007 in Lund, and between April 2006 and October
2007 in Helsingborg. Helsingborg is located approximately 50km
north of Lund. There are nine hospitals in the South Swedish Health
Care Region performing breast cancer surgery. The Lund University
Hospital catchment area serves almost 300000 inhabitants and the
Helsingborg Hospital serves another 250000 inhabitants. Breast cancer
patients are not referred to other hospitals for surgery. We, therefore,
consider this study population-based.
Women were invited to participate regardless of ethnic back-
ground, age, and tumour stage. Patients who had been diagnosed
recently and treated for another type of cancer within the past 10
years were not eligible to participate. The study was approved by
the Ethics Committee of Lund University. Written informed
consents were collected during the preoperative visit at the
Department of Surgery at the Lund University Hospital. At the
same visit, the research nurse collected blood samples (EDTA–
plasma and serum) and recorded the time and date when the blood
samples were drawn. The blood was centrifuged and separated.
Serum, EDTA–plasma, and blood cells were stored at  701C. All
samples were labelled with serial codes to enable blinded analyses.
Body weight, height, waist and hip circumferences, and breast
volumes were measured at the preoperative visit. All patients filled
out a preoperative questionnaire including questions on birth date,
coffee consumption, smoking, alcohol intake, use of exogenous
hormones and concomitant medications, reproductive history, and
family history of cancer. No question enquired about ethnicity.
However, the vast majority of women included were ethnic Swedes.
Information including type of surgery, sentinel node biopsy, and
axillary node dissection was obtained from each patient’s chart.
Tumour size, histological type and grade, axillary node involve-
ment, signs of distant metastases, ER, and progesterone receptor
(PR) status were obtained from each patient’s pathology report.
Histological grade was evaluated according to the procedure
of Elston and Ellis (1991). The grading procedure consisted of
judgement of tubule formation, nuclear pleomorphism, and
mitotic count. The number of mitoses was counted in 10 high-
power fields, and the results were adjusted to the area of the
microscopic field. Each of the three morphological features,
tubules, nuclear pleomorphism, and number of mitoses, was given
a score of 1 to 3 points. The overall histological grade was obtained
by adding the score of each characteristic, resulting in a possible
total score of 3 to 9 points. The histological grade allocation was as
follows: grade-1, 3 to 5 points; grade-2, 6 to 7 points; and grade-3, 8
to 9 points.
Oestrogen receptor and PR status was determined by immuno-
histochemistry using the Dako LSAB kit system (Dako, Glostrup,
Denmark) and antibodies M7047 (ER) and M3569 (PR) (Dako) in
Lund. In Helsingborg, ER and PR status was determined by
immunohistochemistry using the Ventana ultra view kit (760-500)
(Ventana, Illkirch, France) and antibodies 790-4324 (ER) (Ventana)
and NCL-L-PGR-312 (PR) (NovoCastra, NewCastle, UK). Tumours
with more than 10% positive nuclear staining were considered ERþ
or PRþ. Receptor-negative tumours had a positive nuclear staining
of 10% or less. All tumours were analysed at the Department of
Pathology of Lund University Hospital or Helsingborg Hospital.
HER-2/neu status was routinely analysed as of November 2005.
According to data obtained from the Regional Tumor Registry,
on June 25, 2008, a total of 6765 primary female breast cancers
were registered between October 1, 2002, and October 31, 2007, in
the South Swedish Health Care Region. During the same time
period, 893 breast tumours were registered in Lund, of which 866
were primary and received surgery. Five hundred and seventeen of
them (60%) were included in our study. Between April 1, 2006, and
October 31, 2007, a total of 330 breast cancers were registered at
Helsingborg, of which 298 received surgery, and 136 (46%) of these
were included in our study.
Genetic analyses
Genomic DNA was extracted from 300ml of peripheral blood using
the Wizard genomic DNA purification kit (Promega, Madison, WI,
USA).
CYP2C8*3 consists of two polymorphisms (G416A) (rs11572080)
and (A1196G) (rs10509681). CYP2C8*3 (G416A) (rs11572080) was
amplified using PCR primers Fw: 50-NNCCACCCTTGGTTTTTCT
CAACTC-30 and Re: 50-BIOTIN-CCTCACAACCTTGCGGAATTT-30
(Biomers, Ulm, Germany), which yield a 105-bp nucleotide sequence.
PCR was performed in 25-ml reactions using 25ng DNA, 0.2mM
of each primer, 0.2mM of each deoxynucleotide (Amersham
Biosciences, Buckinghamshire, UK), 1.5mM MgCl2 (Applied
Biosystems, Foster City, CA, USA), 1 PCR Gold Buffer (Applied
Biosystems), and 0.5U of AmpliTaq Gold (Applied Biosystems).
CYP2C8*3 (A1196G) (rs10509681) was amplified using PCR
primers Fw: 50-BIOTIN-TTTGTTACTTCCAGGGCACA-30 and Re:
50-NNAAAGTGGCCAGGGTCAAAG-30 (Biomers), which yield a
101-bp nucleotide sequence. PCR was performed in 25-ml reac-
tions using 25ng DNA, 0.2mM of each primer, 0.2mM of each
deoxynucleotide (Amersham Biosciences), 1.5mM MgCl2 (Applied
Biosystems), 1 PCR Gold Buffer (Applied Biosystems), and 0.5U
of AmpliTaq Gold (Applied Biosystems). Both SNPs were run for
298 samples with 100% concordance. We, therefore, genotyped
only (rs11572080) for the remaining 354 samples.
CYP2C8*4 (rs1058930) was amplified using PCR primers Fw:
50-NNGTTTCCCAGGAACTCACAACAAAG-30 and Re: 50-BIOTIN-
AAGCATTACTGGCCTGATCATTT-30 (Biomers), which yield a 255-bp
nucleotide sequence. PCR was performed in 25-ml reactions using
25ng DNA, 0.17mM of each primer, 0.5mM of each deoxynucleo-
tide (Amersham Biosciences), 2.0mM MgCl2 (Applied Biosystems),
1 PCR Gold Buffer (Applied Biosystems), and 0.5U of AmpliTaq
Gold (Applied Biosystems).
CYP2C9*2 (rs1799853) was amplified using PCR primers Fw:
50-NNGTATTTTGGCCTGAAACCCATA-30 and Re: 50-BIOTIN-CA
CCCTTGGTTTTTCTCAACTC-30 (Biomers), which yield a 455-bp
nucleotide sequence. PCR was performed in 25-ml reactions using
25ng DNA, 0.2mM of each primer, 0.2mM of each deoxynucleo-
tide (Amersham Biosciences), 1.5mM MgCl2 (Applied Biosystems),
1 PCR Gold Buffer (Applied Biosystems), and 0.5U of AmpliTaq
Gold (Applied Biosystems).
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50-BIOTIN-TGCACGAGGTCCAGAGAT-30 and Re: 50-NNGATACT
ATGAATTTGGGACTTC-30,w h i c hy i e l da1 5 5 - b pn ucleotide sequence.
PCR was performed in 25-ml reactions using 25ng DNA, 0.2mM of each
primer, 0.2mM of each deoxynucleotide (Amersham Biosciences),
1.5mM MgCl2 (Applied Biosystems), 1 PCR Gold Buffer (Applied
Biosystems), and 0.5U of AmpliTaq Gold (Applied Biosystems).
PSQ and sequencing
The PCR products of CYP2C8*3 (G416A and A1196G), CYP2C8*4,
CYP2C9*2, and CYP2C9*3 were sequenced (PyroGold, Pyro-
sequencing; Biotage, Uppsala, Sweden) according to the manu-
facturer’s instructions and run on pyrosequencing (PSQ) HS 96A.
The following PSQ primers were used: CYP2C8*3(G416A)_PSQ,
50-CGGTCCTCAATGCTC-30; CYP2C8*3(A1196G)_PSQ, 50-ATTTG
GATTAGGAAATTCT-30; CYP2C8*4_PSQ, 50-CAATCCTCGGGACT
TT-30; CYP2C9*2_PSQ, 50-GGGAAGAGGAGCATTGAGGAC-30; and
CYP2C9*3_PSQ, 50-TGGTGGGGAGAAGGTC-30 (Biomers). Results
were analysed using the inbuilt software programme on PSQ HS
96A. For quality control, every fourth sample was run in duplicate
in separate PCR and PSQ reactions.
All different genotypes found in the PSQ reaction were
confirmed by sequencing (Big Dye, Terminator Cycle Sequencing;
Applied Biosystems) according to the manufacturer’s instructions
and run on an ABI 3100 Genetic Analyzer (Applied Biosystems).
In April 2006, the system was upgraded to an ABI Prism 3130xl
Genetic Analyzer (Applied Biosystems). Results were analysed
using the Sequencing Analysis software (Applied Biosystems) and
evaluated using the Sequencher software (Gene Codes Corporation)
current version 4.5.
Validation Validation was performed with separate PCR and
sequencing reactions.
CYP2C8*3: Four hundred and twenty-two samples have been
validated and the concordance rate was 100%.
CYP2C8*4: One hundred and ninety-two samples have been
validated and the concordance rate was 100%.
CYP2C9*2: One hundred and eighty-one samples have been
validated and the concordance rate was 97.2%.
A homozygote CYP2C9*2 reference sample was sometimes
analysed with the PSQ software as a heterozygote instead of a
homozygote. We, therefore, re-evaluated all the heterozygotes to
make sure they were not in fact homozygotes, and they were not.
CYP2C9*3: One hundred and eighty-two samples have been
validated and the concordance rate was 100%.
Statistical analyses
The statistical software PASW 17.0 was used. Tumour character-
istics were compared between different genotypes using Student’s
t-test for continuous variables (age and tumour size) and w
2-test
for categorical variables. Mann–Whitney U-test was used for
tumour size since this variable was not normally distributed.
Tumour size was transformed using natural logarithm to obtain a
better distribution for use in the multivariate linear regression
models. Breast cancer-free survival rates in relation to different
genotypes were assessed using Kaplan–Meier log-rank test and
Cox regression models. A P-value less than 0.05 was considered
significant. All P-values were two-sided. Nominal P-values are
presented without adjustment for multiple testing.
RESULTS
The characteristics of the women are presented in Table 1. Of the
patients, 517 were included in Lund and 135 in Helsingborg. Age at
diagnosis and all tumour characteristics were comparable between
patients from the two hospitals, except for histological grade,
which was higher in Helsingborg patients (w
2-test Po0.001).
The frequencies of CYP2C8 and CYP2C9 polymorphisms are
presented in Table 2a–c. CYP2C8*3 and CYP2C8*4 were in linkage
disequilibrium (LD) and appeared not to be present on the same
allele (Table 2a). Similarly, CYP2C9*2 and CYP2C9*3 were in LD
and appeared to be mutually exclusive (Table 2b). As previously
reported, CYP2C8*3 and CYP2C9*2 were highly, but not perfectly,
linked (Table 2c). None of the polymorphisms differed signifi-
cantly in frequency between patients from the two hospitals.
Based on the above information we constructed the most likely
haplotypes of CYP2C8/9 (Table 3). Six haplotypes were found in
this patient population. More than half of the patients (55.5%)
carried two copies of alleles with wild-type SNPs in all four
positions. Another 37.7% carried one such haplotype. The second
most common haplotype was the combination of CYP2C8*3
and CYP2C9*2, and was present in 17.9% of patients. CYP2C8*4
Table 1 Preoperative characteristics of the 652 patients
All patients
Median or % IQR Missing
Age at diagnosis (years) 59.6 50.7–67.0 0
Height (cm) 165 162–170 1
Weight (kg) 68 61–76 1
Body mass index (BMI) (kgm
 2) 24.6 22.3–27.7 2
Waist-to-hip ratio (WHR) 0.83 0.78–0.88 4
Total breast volume (cm
3) 1000 700–1600 9
Age at menarche (years) 13 12–14 5
Premenopausal 24.5% 4
Age at menopause 50 47–52 192
Age at first full-term pregnancy
a 24 21–28 96
Parity 2 1–3 0
Ever oral contraceptive use 70.1% 0
Ever hormone replacement therapy use 45.6% 1
Abstainer of alcohol (%) 12.1% 1
Current smoker (%) 22.0% 1
Daily coffee consumption (cups) 3 2–4 2
11 relative with breast cancer 19.2% 21
Abbreviation: IQR¼interquartile range.
aAmong parous women only.
Table 2 (a–c) The relationship between CYP2C8 and CYP2C9
genotypes in the breast cancer patient group
(a) CYP2C8*1/*1 CYP2C8*1/*4 CYP2C8*4/*4 n
CYP2C8*1/*1 445 76 3 524
CYP2C8*1/*3 116 5 0 121
CYP2C8*3/*3 70 0 7
n 568 81 3 652
(b) CYP2C9*1/*1 CYP2C9*1/*3 CYP2C9*3/*3 n
CYP2C9*1/*1 438 67 2 507
CYP2C9*1/*2 124 11 0 135
CYP2C9*2/*2 80 0 8
n 570 78 2 650
(c) CYP2C9*1/*1 CYP2C9*1/*2 CYP2C9*2/*2 n
CYP2C8*1/*1 498 25 1 524
CYP2C8*1/*3 9 110 1 120
CYP2C8*3/*3 01 6 7
n 507 136 8 652
Abbreviation: CYP¼cytochrome P450. Table 2a shows linkage disequilibrium (LD)
between the CYP2C8*3 and CYP2C8*4 genotypes among the 652 breast cancer
patients included. Table 2b shows LD between the CYP2C9*2 and CYP2C9*3
genotypes. Table 2c confirms the previously reported imperfect LD between
CYP2C8*3 and CYP2C9*2. Genotype data on CYP2C9*2 were missing for one
woman and CYP2C9*3 genotype data were missing for another woman.
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remaining three positions, and was present in nearly 13% of
the patients. CYP2C9*3 in combination with wild-type SNPs in the
remaining three positions was present in over 12% of the patients.
Other combinations were rare or did not exist.
Tumour characteristics in relation to polymorphisms in
CYP2C8 and CYP2C9
Patients without preoperative treatment and at least one copy of
CYP2C8*3, CYP2C9*2,o rCYP2C9*3 did not significantly differ
with respect to age at diagnosis, invasive tumour size, axillary node
status, histological grade, and ER or PR status when compared
with the wild-type for each SNP. However, carrying at least one
copy of CYP2C8*4 was associated with a significantly lower
frequency of axillary lymph node involvement (21% versus 38%;
P¼0.002) in spite of a lower frequency of PR-positive tumours
(57% versus 71%; P¼0.012) and similar tumour sizes compared
with patients without this SNP (Table 4).
Haplotypes of CYP2C8/9 in relation to tumour
characteristics
Only the haplotype allele containing the CYP2C8*4 was associated
with the tumour characteristics as presented above.
Factors associated with axillary lymph node status
Since women with the CYP2C8*4 appeared to have lower risk for
lymph node involvement, we performed multivariate logistic
regression analyses to elucidate which factors were associated
with axillary lymph node status. Patients with invasive tumours,
who had not received neo-adjuvant treatment or interstitial laser
thermotherapy, were included in the analyses.
Only increasing tumour size was associated with axillary lymph
node spread (Po0.0001), adjusted for age at diagnosis, histological
grade, and ER and PR status. We then added the haplotype with
the CYP2C8*4 allele to the model. The number of CYP2C8/9 *1/*4/
*1/*1 copies was significantly associated with a decreased
frequency for axillary lymph node involvement (odds ratio (OR)
0.40; 95% Confidence interval (CI) 0.22–0.74; P¼0.003), adjusted
for tumour size, histological grade, age at diagnosis, and ER and
PR status.
In women with invasive tumour sizes of 20mm or less, the
CYP2C8/9 *1/*4/*1/*1 haplotype allele was not associated with
lymph node status. Conversely, in women with tumours that were
21mm or larger, each CYP2C8/9 *1/*4/*1/*1 allele was associated
with significantly lower risk for lymph node involvement (OR 0.18,
95% CI 0.06–0.54; P¼0.002), while each copy of the CYP2C8/9 *3/
*1/*2/*1 allele was associated with a more than doubled risk of
lymph node involvement (OR 2.53, 95% CI 0.97–6.64; P¼0.06),
adjusted for tumour size, histological grade, age at diagnosis, and
ER and PR status. The associations between the CYP2C8/9 *1/*4/
*1/*1 haplotype and CYP2C8/9 *3/*1/*2/*1 haplotypes and lymph
node involvement was different depending on the invasive
tumour size (exp(b)¼0.33; Pinteraction¼0.10 and exp(b)¼3.2;
Pinteraction¼0.040, respectively, when entered into the same
model). The effects were somewhat stronger when the interaction
terms were entered individually (exp(b)¼0.33; Pinteraction¼0.066
for CYP2C8/9 *1/*4/*1/*1 and exp(b)¼3.4; Pinteraction¼0.028 for
CYP2C8/9 *3/*1/*2/*1). Since CYP2C8*3 and CYP2C9*2 are not in
perfect LD, we also examined each SNP separately in women with
tumours 21mm or larger. For each copy of the CYP2C8*3 allele,
the adjusted odds for nodal involvement was 2.74 (95%CI 1.16–
6.51; P¼0.022). For each copy of CYP2C9*2, the adjusted OR was
2.81 (95%CI 1.18–6.67; P¼0.020).
Breast cancer-related events
We then investigated the association between CYP2C8/9 haplo-
types in relation to early breast cancer events (local, regional, new
breast cancer, distant metastases, or death from breast cancer) by
December 2008. The median follow-up time is now 25 months
(range 0–62 months). During this period, 52 breast cancer-related
events were reported in women with primary invasive breast
cancer, excluding four women who were found to have distant
metastases on the postoperative metastatic screen. Seven of these
women had received some form of neoadjuvant therapy, three
women had received preoperative interstitial laser thermotherapy,
14 women had received postoperative polychemotherapy, 23
women had received tamoxifen, and eight women had received
an aromatase inhibitor prior to recurrence (some women received
more than one adjuvant treatment). The CYP2C8 enzyme is
involved in paclitaxel metabolism, but only one woman with a
Table 3 shows the frequencies of the most likely CYP2C8/9 haplotypes
sorted according to their frequency among the breast cancer patients
No allele One allele Two alleles Missing
CYP2C8/9*1/*1/*1/*1 42 (6.4) 246 (37.7) 362 (55.5) 2 (0.3)
CYP2C8/9*3/*1/*2/*1 533 (81.7) 111 (17.0) 6 (0.9) 2 (0.3)
CYP2C8/9*1/*4/*1/*1 566 (86.8) 81 (12.4) 3 (0.5) 2 (0.3)
CYP2C8/9*1/*1/*1/*3 570 (87.4) 78 (12.0) 2 (0.3) 2 (0.3)
CYP2C8/9*1/*1/*2/*1 623 (95.6) 26 (4.0) 1 (0.2) 2 (0.3)
CYP2C8/9*3/*1/*1/*1 640 (98.2) 10 (1.5) 0 (0.0) 2 (0.3)
Abbreviation: CYP¼cytochrome P450. These were constructed based on the
information obtained from Tables 2a–c.
Table 4 Characteristics of the 612 tumours from the patients not
treated with preoperative interstitial laser thermo therapy (n¼11 and 1
uncertain) or neoadjuvant therapy (n¼28) in this study
n (%) Any CYP2C8*4 allele (%)
Invasive tumour size
pis 14 (2.3) 28.6
pT1 432 (70.6) 12.0
PT2 152 (24.8) 13.8
pT3 12 (12.0) 8.3
pT4 1 (0.2) 0
Missing 3 (0.5)
Axillary lymph node involvement
pN  389 (63.8) 15.9
pN+ 220 (35.9) 7.3
Missing 3 (0.5)
Histological grade
Grade 1 156 (25.5) 9.3
Grade 2 312 (51.0) 12.2
Grade 3 142 (23.2) 16.9
Missing 3 (0.5)
Hormone receptor status
ER+/PR+ 411 (67.2) 10.2
ER+/PR  111 (18.1) 16.2
ER /PR  72 (11.8) 19.4
ER /PR+ 4 (0.7) 0
Missing 13 (2.1)
Abbreviations: CYP¼cytochrome P450; ER¼oestrogen receptor; PR¼progesterone
receptor. The CYP2C8*4 allele was the only genotype that was associated with
tumour characteristics. The percentage of patients with at least one CYP2C8*4 allele
is indicated in relation to the tumour characteristics. *Large and inflammatory
tumours were treated by neoadjuvant therapy; therefore there is no information
presented on these tumours.
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based regimen and four other women with events had received a
docetaxel-based regimen as neoadjuvant treatment.
The increasing number of CYP2C8*3/*1/*2/*1 alleles was
associated with shorter disease-free survival in 297 ER-positive
patients with invasive tumours who had received tamoxifen prior
to the last follow-up or event (log rank 6.36; 1 df; P¼0.012), HR
2.54 (95% CI 1.11–5.79; P¼0.027), adjusted for age, tumour size,
axillary lymph node status, PR status, histological grade, and other
haplotypes. None of the other factors adjusted for in the model
were significantly associated with early events.
Since there was a high degree of LD between CYP2C8*3 and
CYP2C9*2, we also examined the risk of event in women the
CYP2C8*3 allele. The results were stronger (log rank 8.16; 1 df;
P¼0.004), adjusted HR 8.56 (95% CI 1.53–51.1; P¼0.015) per
copy. Since there were only few women who were homozygous for
CYP2C8*3, we also examined the HR for women with any
CYP2C8*3 allele (log rank 4.47 1 df; P¼0.034), adjusted HR 9.10
(95%CI 1.39–59.6; P¼0.021) (Figure 1). There was no significant
effect of carrying at least one CYP2C9*2, but it went in the opposite
direction, adjusted HR 0.22 (95%CI 0.33–1.51; P¼0.12).
DISCUSSION
This study is, to our knowledge, the first to have constructed
CYP2C8/9 haplotypes including the CYP2C8*4 polymorphism and
to have shown that this polymorphism is unlikely to be present on
the same allele as CYP2C8*3 in a Swedish population. A recent
paper on a small Spanish population reported a similar finding
(Dorado et al, 2008), but the frequency of CYP2C8*4 was much
lower in that study. The frequencies of CYP2C8*3 and CYP2C8*4
were similar to those reported in the HapMap project for European
populations (NCBI SNP homepage, 2008), and the frequencies of
the CYP2C9*2 and CYP2C9*3 were in line with those reported by
Yasar et al (1999) from a Swedish population of 430 unrelated
healthy people.
This is the first study to report an association between decreased
odds for lymph node involvement and CYP2C8*4 and an over
twofold increased odds for lymph node involvement among
CYP2C8/9 *3/*1/*2/*1 carriers with invasive tumour sizes over
20mm. CYP2C8*3 and CYP2C8*4 have both been reported to have
lower metabolic activity than the wild type (Bahadur et al, 2002),
but the associations between these polymorphisms and axillary
nodal involvement went in opposite directions in the current
study. Since CYP2C8*3 was in strong LD with CYP2C9*2, it is likely
that the association between CYP2C8*3 and nodal status is actually
reflecting the association between the CYP2C9*2 polymorphism
and nodal status.
We found that an increasing number of CYP2C8/9 *3/*1/*2/*1
haplotype alleles and especially CYP2C8*3 alleles was associated
with increased hazard of early breast cancer-related events in
tamoxifen-treated patients. Tamoxifen is a moderate CYP2C8
inhibitor (Walsky et al, 2005), a CYP2C9 substrate (Jin et al, 2005),
and significantly inhibits CYP2C9 activity in breast cancer patients
(Boruban et al, 2006). CYP2C9 is involved in tamoxifen activation,
although neither CYP2C9*2 nor CYP2C9*3, which have lower
activity than the wild type, were significantly associated with the
levels of the potent tamoxifen metabolite endoxifen in one study
(Jin et al, 2005). The effect of CYP2C8 polymorphisms on
endoxifen levels has, to our knowledge, not been investigated.
Since the LD between CYP2C8*3 and CYP2C9*2 was incomplete,
we also examined the effect of each SNP separately in the model,
and while CYP2C8*3 was associated with significant increased
hazard of early breast cancer-related events, CYP2C9*2 was
associated with non-significant decreased hazard. If our finding
is replicated, the CYP2C8*3 may be used to identify patients who
may recur early when treated with tamoxifen and who should be
offered additional or different treatment.
Currently, no genotype data are used prior to selection of
tamoxifen or aromatase inhibitors for breast cancer patients with
ER-positive tumours warranting adjuvant endocrine treatment.
CYP2D6 has been shown to significantly affect the levels of
endoxifen and clinical outcome after tamoxifen treatment (Jin
et al, 2005; Goetz et al, 2008). To our knowledge there is no
association between CYP2D6 and CYP2C8/9, and these genes are
located on different chromosomes. It is, therefore, unlikely that the
increased risk for early recurrences observed in CYP2C8*3 carriers
would be explained by CYP2D6 polymorphisms. Schroth et al.
studied CYP2D6, CYP2C19, CYP3A5, CYP2B6, and CYP2C9 in
tamoxifen-treated women. They reported that the CYP2C19*17
allele partly compensates for non-functioning CYP2D6 alleles and
showed that carriers of one CYP2D6-null allele could be further
stratified according to their CYP2C19*17 genotype with respect to
tamoxifen response (Schroth et al, 2007). The genotypes of
CYP3A5, CYP2B6, and CYP2C9 were not significantly associated
with tamoxifen response, which is in line with our finding with
respect to CYP2C9*2 and CYP2C9*3, but they did not examine
CYP2C8.
The St Gallen guidelines recommend that extensive peritumoral
vascular invasion be used as a prognostic factor (Goldhirsch et al,
2007). The degree of angiogenesis is not yet routinely evaluated in
the clinical setting in Sweden, and we could, therefore, not evaluate
whether there was any association between peritumoral vascular
invasion and CYP2C8/9 haplotypes. It is plausible that we could
have found an association, since CYP2C9-derived EETs stimulate
angiogenesis (Michaelis et al, 2003). CYP2C9-derived EETs do so
by a mechanism involving activation of the EGFR (Michaelis et al,
2003). One study reported high expression of EGFR to be inversely
correlated with nodal metastases and shorter, distant disease-free
survival in a group of breast cancer patients who had received 2
years of adjuvant tamoxifen treatment (Dihge et al, 2008). This is
not fully compatible with our finding, as we found both a higher
frequency of nodal involvement with the CYP2C8/9 *3/*1/*2/*1
genotype (in tumours larger than 20mm) and a higher risk of any
type of breast cancer recurrence, especially in women treated with
tamoxifen. In small tumours, angiogenesis is also a predictor of
nodal status (Arisio et al, 2000), and it is thus possible that women
with the CYP2C8/9 *3/*1/*2/*1 genotype have tumours that are
more likely to metastasise through increased angiogenesis.
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Figure 1 The figure shows that having at least one copy of the
CYP2C8*3 allele conferred an increased risk for an early breast cancer-
related event in tamoxifen-treated women with invasive ER-positive
cancers (log rank 4.47; 1 df; P¼0.034). HR 9.10 (95% CI 1.39-59.6;
P¼0.021), adjusted for invasive tumour size, age, PR, histological grade,
axillary lymph node status, CYP2C8*4, CYP2C9*2, and CYP2C9*3. The
number of patients at each time point is indicated.
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determined by polymorphic variants, but also by use of CYP2C8-
and CYP2C9-inhibiting compounds, including several drugs, as
reviewed by Ingelman-Sundberg et al (2007). In the present study
we enquired only about the use of all concomitant medications
during the past week and lack information on long-term use of any
of the medications. However, this information is not relevant in
relation to tumour characteristics as the tumours were formed
many years prior to diagnosis.
HER-2/neu status was not analysed routinely before November
2005, and we have therefore not been able to evaluate the correla-
tion between HER-2 overamplification and CYP2C8/9 haplotypes.
Histological grade was assessed according to the procedure of
Elston and Ellis (1991). In the current study histological grade was
not associated with early recurrences in either group (data not
shown), but the median follow-up time is still short.
Our material consisted of a series of primary breast cancer
patients, where the only exclusion criteria were any previous breast
cancer diagnosis and other cancer diagnosed within the past 10
years. Approximately 60% of the patients operated on in Lund and
46% of the patients operated on in Helsingborg during the study’s
enrolment period were included. Our sample from Lund was
similar to all patients from Lund with respect to age and ER and
PR status. The patients from Helsingborg were somewhat older
and had fewer PR-positive tumours as compared with the region as
a whole, while the subset of patients who were included in this
study was comparable to those included from Lund and the whole
South Swedish region with respect to age and hormone-receptor
status. There are several potential explanations for why receptor
status may be different in Helsingborg patients. The patients in
Helsingborg are somewhat older and different sets of antibodies
are used at different Departments of pathology. ER and PR status
was independently re-assessed by 22 pathologists from nine
hospitals and the kappa values were 0.78 for ER and 0.72 for PR
in 2003 (Chebil et al, 2003). Provided that these markers are used
for selection of breast cancer treatment, quality assurance is
ongoing. The frequency of HRT use may also differ between the
two cities and HRT treatment is associated with a higher frequency
of ER-positive tumours (Glass et al, 2007). As patients who were
included did not differ with respect to ER, PR, or prior HRT use,
we were unable to explain why patients from Helsingborg in
general would have fewer PR-positive tumours.
In conclusion, we found that the frequencies of CYP2C8*3 and
CYP2C8*4, and CYP2C9*2 and CYP2C9*3 were comparable to
those of healthy European populations. Each copy of the CYP2C8/9
*1/*4/*1/*1 allele was associated with significantly lower risk for
nodal involvement, while each copy of the CYP2C8/9 *3/*1/*2/*1
allele was associated with increased risk for nodal involvement in
tumours larger than 20mm. Moreover, the CYP2C8*3 allele was
associated with early breast cancer-related events in women
treated with tamoxifen. Since this is the first study reporting an
association between CYP2C8 and tamoxifen response, and the
median follow-up time is still short, the finding warrants
confirmation. If confirmed, it is possible that CYP2C8*3 can be
used as a genetic marker for prediction of treatment response to
tamoxifen.
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